Treatment with the histone deacetylase inhibitor valproic acid subsequently increases LIFR expression in human MCF7 breast cancer cells in vitro, suggesting that targeting LIFR, a downstream factor in PTHrP signaling, may effectively maintain tumor cells in a dormant state to prevent metastatic outgrowth. This evidence concerns the gene LIFR and breast carcinoma.